U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Les Produits Chimiques B.G.R., Inc. - 542247 - 05/21/2020
  1. Warning Letters

CLOSEOUT LETTER

Les Produits Chimiques B.G.R., Inc. MARCS-CMS 542247 —

Reference #:
320-18-64
Product:
Drugs
Recipient:
Recipient Name
Ms. Nathalie A. Bélanger
Recipient Title
Vice-President and Owner
Les Produits Chimiques B.G.R., Inc.

600 Avenue Delmar
Pointe-Claire QC H9R 4A8
Canada

Issuing Office:
Division of Drug Quality II

United States

Dear Ms. Bélanger:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-18-64 dated July 23, 2018.

Based on our evaluation, it appears that you have adequately addressed the deviations contained in this warning letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.

The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should deviations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Bill Fowler
Compliance Officer
Division of Drug Quality II

Back to Top